Prevalence, Severity, and Treatment of Community-Acquired Methicillin-Resistant Staphylococcus Aureus (CA-MRSA) Skin and Soft Tissue Infections in 10 Medical Clinics in Texas: A South Texas Ambulatory Research Network (STARNet) Study

References

1. 1.↵
   1. Hersh AL,
   2. Chambers HF,
   3. Maselli JH,
   4. Gonzales R

   . National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med 2008;168:1585–91

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Pallin DJ,
   2. Egan DJ,
   3. Pelletier AJ,
   4. et al

   . Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med 2008;51:291–8

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Taira BR,
   2. Singer AJ,
   3. Thode HC Jr.,
   4. Lee CC

   . National epidemiology of cutaneous abscesses: 1996 to 2005. Am J Emerg Med 2009;27:289–92

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Moran GJ,
   2. Krishnadasan A,
   3. Gorwitz RJ,
   4. et al

   . Methicillin-resistant S aureus infections among patients in the emergency department. N Engl J Med 2006;355:666–74

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Lee MC,
   2. Rios AM,
   3. Aten MF,
   4. et al

   . Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant S aureus. Pediatr Infect Dis J 2004;23:123–7

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Fridkin SK,
   2. Hageman JC,
   3. Morrison M,
   4. et al

   . Methicillin-resistant Staphylococcus Aureus disease in three communities. N Engl J Med 2005;352:1436–44

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Paydar KZ,
   2. Hansen SL,
   3. Charlebois ED,
   4. et al

   . Inappropriate antibiotic use in soft tissue infections. Arch Surg 2006;141:850–4

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Ruhe JJ,
   2. Smith N,
   3. Bradsher RW,
   4. Menon A

   . Community-onset methicillin-resistant Staphylococcus Aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 2007;44:777–84

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Duong M,
   2. Markwell S,
   3. Peter J,
   4. Barenkamp S

   . Randomized, controlled trial of antibiotics in the management of community-acquired skin abscesses in the pediatric patient. Ann Emerg Med 2010;55:401–7

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Rajendran PM,
    2. Young D,
    3. Maurer T,
    4. et al

    . Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus Aureus infection. Antimicrob Agents Chemother 2007;51:4044–8

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Schmitz GR,
    2. Bruner D,
    3. Pitotti R,
    4. et al

    . Randomized controlled trial of trimethoprim-sulfamethoxazole for uncomplicated skin abscesses in patients at risk for community-associated methicillin-resistant Staphylococcus Aureus infection. Ann Emerg Med 2010;56:283–7

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Ruhe JJ,
    2. Menon A

    . Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant S aureus. Antimicrob Agents Chemother 2007;51:3298–303

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Szumowski JD,
    2. Cohen DE,
    3. Kanaya F,
    4. Mayer KH

    . Treatment and outcomes of infections by methicillin-resistant Staphylococcus Aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007;51:423–8

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Frazee BW,
    2. Lynn J,
    3. Charlebois ED,
    4. et al

    . High prevalence of methicillin-resistant Staphylococcus Aureus in emergency department skin and soft tissue infections. Ann Emerg Med 2005;45:311–20

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. King MD,
    2. Humphrey BJ,
    3. Wang YF,
    4. et al

    . Emergence of community-acquired methicillin-resistant Staphylococcus Aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006;144:309–17

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Frei CR,
    2. Miller ML,
    3. Lewis JS 2nd.,
    4. et al

    . Trimethoprim-sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections. J Am Board Fam Med 2010;23:714–9

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Parchman ML,
    2. Munoz A

    . Risk factors for methicillin-resistant Staphylococcal aureus skin and soft tissue infections presenting in primary care: a South Texas Ambulatory Research Network (STARNet) study. J Am Board Fam Med 2009;22:375–9

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Khawcharoenporn T,
    2. Tice A

    . Empiric outpatient therapy with trimethoprim-sulfamethoxazole, cephalexin, or clindamycin for cellulitis. Am J Med 2010;123:942–50

    OpenUrlCrossRefPubMed
19. 19.↵
    CLSI. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S17. Wayne, PA: Clinical and Laboratory Standards Institute; 2007.
20. 20.↵
    US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: uncomplicated and complicated skin and skin structure infections: developing antimicrobial drugs for treatment. http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm071185.pdf. Accessed January 20, 2011.
21. 21.↵
    US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Draft guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment. August 2010. http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/ ucm071185.pdf. Accessed January 21, 2011.
22. 22.↵
    1. Eron LJ,
    2. Lipsky BA,
    3. Low DE,
    4. et al.

    ; Expert Panel on Managing Skin and Soft Tissue Infections. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003;52(Suppl S1):i3–17.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Ki V,
    2. Rotstein C

    . Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can J Infect Dis Med Microbiol 2008;19:173–84

    OpenUrlPubMedWeb of Science
24. 24.↵
    1. Stevens DL,
    2. Bisno AL,
    3. Chambers HF,
    4. et al

    . Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373–406

    OpenUrlFREE Full Text
25. 25.↵
    1. Gorwitz RJ,
    2. Jernigan DB,
    3. Powers JH,
    4. Participants in the CDC Convened Experts' Meeting on Management of MRSA in the Community

    . Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. Available at http://www.cdc.gov/ncidod/dhqp/ar_mrsa_ ca.html. Accessed January 10, 2011.
26. 26.↵
    1. Liu C,
    2. Bayer A,
    3. Cosgrove SE,
    4. et al

    . Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus Aureus infections in adults and children. Clin Infect Dis 2011;52:18–55

    OpenUrlCrossRef
27. 27.↵
    1. LoVecchio F,
    2. Perera N,
    3. Casanova L,
    4. et al

    . Board-certified emergency physicians' treatment of skin and soft tissue infections in the community-acquired methicillin-resistant Staphylococcus Aureus era. Am J Emerg Med 2009;27:68–70

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Lewis JS 2nd.,
    2. Jorgensen JH

    . Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned? Clin Infect Dis 2005;40:280–5

    OpenUrlAbstract/FREE Full Text
29. 29.↵
    1. Draghi DC,
    2. Sheehan DF,
    3. Hogan P,
    4. Sahm DF

    . Current antimicrobial resistance profiles among methicillin-resistant Staphylococcus Aureus encountered in the outpatient setting. Diagn Microbiol Infect Dis 2006;55:129–33

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Stevens DL,
    2. Ma Y,
    3. Salmi DB,
    4. et al

    . Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant S aureus. J Infect Dis 2007;195:202–11

    OpenUrlAbstract/FREE Full Text